PD-1 Antibody Expressing mesoCAR-T Cells for Mesothelin Positive Advanced Solid Tumor

Summary

This is a single-arm, open-label, one center clinical study, to determine the safety and efficacy of infusion of autologous T cells engineered to target mesothelin and express PD-1 antibodies in adult patients with advanced recurrent or refractory malignant solid tumors, which were positive expression of mesothelin.

Conditions

• Advanced Solid Tumor

Interventions

BIOLOGICAL

PD-1 antibody expressing mesoCAR-T cells

Patients with mesothelin positive cancer will be infused the PD-1 antibody expressing mesoCAR-T cells. The modified mesoCAR-T cells can specifically kill mesothelin positive cancer cells and secrete PD-1 antibody, which could enhance the cytotoxicity of mesoCAR-T cells and activate the tumor infiltrating lymphocytes.

Sponsors & Collaborators

• Shanghai Cell Therapy Research Institute

  lead OTHER

Principal Investigators

• Qijun Qian, PhD · Shanghai Cell Therapy Research Institute

• Huajun Jin, PhD · Shanghai Cell Therapy Research Institute

• Qing Xu, PhD · Shanghai 10th People's Hospital

• Zhiwei Zhang, PhD · Shanghai Cell Therapy Research Institute

• Yan Sun · Shanghai Cell Therapy Research Institute

• Huimei Li, PhD · Shanghai Cell Therapy Research Institute

• Juemin Fang, PhD · Shanghai 10th People's Hospital

• Song Gao, PhD · Shanghai 10th People's Hospital

• Xianling Guo · Shanghai 10th People's Hospital

• Hui Wang · Shanghai 10th People's Hospital

• Zhongzheng Zhu · Shanghai 10th People's Hospital

• Jianhua Chen · Shanghai 10th People's Hospital

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2018-08-06

Primary Completion

2020-08-03

Completion

2020-12-03

Countries

• China

Study Locations